Bill
S 1211
Idaho S 1211 would let ivermectin for human use be sold OTC without prescription, instantly effective, reshaping pharmacy stocking and consumer access.
Below is a concise, objective summary of the materials you supplied. The documents appear to conflates more than one distinct piece of legislation that share the identifier “S 1211” (different jurisdictions). I summarize each identifiable bill separately and note procedural details and likely effects. If you want a deeper summary of one specific bill/jurisdiction, tell me which one.
Summary — Key observation
- The provided packet mixes at least two different bills labeled “S 1211”: (A) an Idaho Senate bill that would make ivermectin for human use available over‑the‑counter; and (B) a Massachusetts Senate bill about conditions of release in Superior Court. There are also scattered references to other sponsors and related bill numbers that do not align clearly with either text. Below are separate summaries for the two identifiable bills.
1) Idaho — S 1211 (Ivermectin sold without prescription)
- Title / Purpose: Amends Title 37 (public health) to allow ivermectin suitable for human use to be sold and purchased over the counter (OTC) without a prescription or consultation with a health‑care professional.
- Key provisions:
- Adds new Section 37‑135, Idaho Code: defines “over‑the‑counter medication” and provides that, notwithstanding other law, ivermectin suitable for human use may be sold/purchased as OTC without prescription or consultation.
- Declares an emergency so the act takes effect immediately upon passage and approval.
- Sponsors / Support: Multiple Idaho legislators listed as sponsors/co‑sponsors in the packet (e.g., Senators Anthon, Nichols; many House co‑sponsors).
- Fiscal/Administrative impact: Fiscal note (prepared by a proponent) states “no significant fiscal impact,” claiming no additional state regulatory costs and possible minor reductions in provider burden.
- Who is affected:
- Consumers: would be able to buy ivermectin for human use without prescription.
- Pharmacies/retailers: could sell human‑use ivermectin OTC; may need to adapt inventory/labeling practices.
- Health care providers: potentially reduced prescription workload; possible public health/clinical consequences.
- State agencies/regulators: fiscal note asserts no major enforcement or oversight costs.
- Procedural status (per packet): Records show Senate and House actions in early April 2025 and indicate the bill was signed by the Governor and became law (Session Law Chapter 334) effective April 14, 2025.
- Potential impacts/considerations: broader consumer access and reduced access barriers; public‑health/safety considerations relating to self‑medication and appropriate clinical use; pharmacy practice and labeling; possible legal questions about conflicting federal guidance or standards for prescription/OTC status.
2) Massachusetts — S.1211 (Conditions of release in Superior Court)
- Title / Purpose: “An Act regarding conditions of release in Superior Court.” Seeks to expand the types of conditions a judge may impose when setting release.
- Key provisions:
- Amends section 57 of chapter 276 (General Laws) to allow the court, if necessary, to order defendants to abide by specified restrictions on personal associations or conduct as a condition of release.
- Explicit example: the court may require avoiding all contact with an alleged victim and any potential witnesses who may testify concerning the offense.
- Amends cross‑references (e.g., section 58B) to incorporate the change.
- Sponsors / Procedural: Filed by Senator Michael O. Moore (Senate docket filed 01/13/2025); referred to the Judiciary. The bill text shows insertion language to broaden permissible release conditions.
- Who is affected:
- Criminal defendants: may be subject to additional personal‑association restrictions as release conditions.
- Victims and witnesses: added statutory protection by allowing courts to bar contact.
- Courts and pretrial services: will implement and monitor such conditions.
- Procedural status in packet: docketed and referred to Judiciary; appears to be in committee/legislative consideration (no final enactment shown in the provided materials).
Notes and next steps
- The materials you provided combine multiple jurisdictions and possibly other unrelated references (e.g., a line listing Senate sponsors “Richard J. Durbin” and “Tammy Duckworth,” and a federal‑style “HR 2506” cross reference). Please confirm which jurisdiction and which S.1211 you want a focused, expanded summary or legal analysis of (Idaho OTC ivermectin law vs. Massachusetts conditions‑of‑release bill), and I will produce a single detailed summary or a legislative impact memo.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
